Observer-Blind, Randomized, Controlled Study of Immunogenicity and Safety of SARS-Cov-2 Protein Subunit Recombinant Vaccine (Bio Farma) as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older
Latest Information Update: 09 Jun 2025
At a glance
- Drugs SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary) ; Tozinameran
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Sponsors PT Bio Farma
Most Recent Events
- 03 Jun 2025 Status changed from recruiting to completed.
- 02 Sep 2022 New trial record